Davis Polk advised Shire plc in connection with the divestiture of its DERMAGRAFT assets to Organogenesis Inc. The DERMAGRAFT assets comprise the key operating assets relating to the development, manufacture and sale of the DERMAGRAFT product.

DERMAGRAFT is a living skin substitute indicated for use in the treatment of full-thickness diabetic foot ulcers and is approved for use in the United States and Canada. Shire enables people with life-altering conditions to lead better lives through the development and marketing of innovative specialty medicines to meet significant unmet patient needs. Organogenesis is a regenerative medicine company that takes living therapies from research and development to successful commercialization.

The Davis Polk corporate team included partner William J. Chudd, and associates Peter M. Lamb and Katherine Tsai. Partner Michael Mollerus and associate Thomas D. Phelan provided tax advice. Counsel Cynthia Akard provided executive compensation advice. Partner Ronan P. Harty and counsel Michael N. Sohn provided antitrust and competition advice. Associate Pritesh P. Shah provided intellectual property advice. Counsel Susan D. Kennedy provided real estate advice. Members of the Davis Polk team are based in the New York, Menlo Park and Washington DC offices.

www.davispolk.com